This article is more than 5 years old. Information may no longer be current.
Zimmer signs agreement with Beijing Drug Administration
Click Here to Manage Email Alerts
Zimmer Holdings Inc. has signed a memorandum of agreement with Beijing Drug Administration to jointly hold training sessions at Montagne, Zimmer’s wholly-owned Chinese subsidiary.
“This collaboration with the Beijing Drug Administration (BJDA) marks a new milestone for Zimmer in China,” David Dvorak, president and chief executive officer of Zimmer, stated in a company press release. “Cooperating with BJDA, we are strengthening our commitment to the Chinese market. The knowledge and expertise Zimmer’s employees and the state regulators will share with one another will help to elevate orthopedic medicine in China.”
Under the terms of agreement, BJDA will provide Zimmer with professional training regarding Chinese laws and regulations related to the manufacture and sale of medical devices. In turn, Zimmer will share experience in areas, including research, development, inspection, clinical use and quality systems management.
According to the release, the trainings will be dedicated to the mutual sharing of knowledge and expertise in research, development, quality and regulation related to musculoskeletal health, allowing BJDA to gain industry knowledge and to understand Zimmer and its products through dialogues and trainings undertaken by its state inspectors. The goal of the agreement also includes strengthening production and inspection expertise at Chinese medical device companies to ensure the delivery of safe and quality orthopedic medical devices.